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Abstract
The purpose of this special issue in BMC Neurology is to summarize advances in our understanding of the
pathological, immunological, imaging and clinical concepts of gray matter (GM) pathology in patients with
multiple sclerosis (MS). Review articles by Lucchinetti and Popescu, Walker and colleagues, Hulst and colleagues
and Horakova and colleagues summarize important recent advances in understanding GM damage and its
implications to MS pathogenesis. They also raise a number of important new questions and outline comprehensive
approaches to addressing those questions in years to come. In the last decade, the use of immunohistochemistry
staining methods and more advanced imaging techniques to detect GM lesions, like double inversion recovery,
contributed to a surge of studies related to cortical and subcortical GM pathology in MS. It is becoming more
apparent from recent biopsy studies that subpial cortical lesions in early MS are highly inflammatory. The
mechanisms responsible for triggering meningeal inflammation in MS patients are not yet elucidated, and they
should be further investigated in relation to their role in initiating and perpetuating the disease process.
Determining the role of antigens, environmental and genetic factors in the pathogenesis of GM involvement in MS
is critical. The early involvement of cortical and subcortical GM damage in MS is very intriguing and needs to be
further studied. As established in numerous cross-sectional and longitudinal studies, GM damage is a better
predictor of physical disability and cognitive impairment than WM damage. Monitoring the evolution of GM
damage is becoming an important marker in predicting future disease course and response to therapy in MS
patients.
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Editorial
Multiple sclerosis (MS) has traditionally been viewed
and studied as a chronic inflammatory demyelinating
disorder of the central nervous system (CNS) that pre-
dominantly involves the white matter (WM). Pathology
studies conducted as early as the 19th century have
already recognized that MS affects not only the WM
but also the gray matter (GM), which somehow got
neglected over the years [1]. However, in the last dec-
ade, substantial pathological, immunological and ima-
ging evidence confirmed that tissue damage in the GM
is a key component of the disease process in MS and
that it occurs from the earliest clinical stages [2-5].
During the past few years, the number of studies investi-
gating GM damage in MS has increased exponentially.
This special issue of BMC Neurology includes four
review articles. One of the primary aims is to provide an
educational update not only to general neurologists but
also to MS specialists and scientists studying MS by
summarizing important recent advances in our under-
standing of GM damage and its implications to MS
pathogenesis. The authors and topics of the articles
have been chosen by the guest editors to provide a
state-of-the-art review of this rapidly emerging field in
MS. The article by Lucchinetti and Popescu focuses on
pathology, [4] the article by Walker and colleagues on
immunology, [3] by Hulst and colleagues on imaging [2]
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and by Horakova and colleagues on clinical [5] features
of GM involvement in patients with MS.
In the last decade, advanced tissue processing and
immunohistochemistry methods, including staining for
myelin basic protein (MBP) and proteolipid protein
(PLP), [6-8] and more advanced magnetic resonance
imaging (MRI) techniques to detect GM lesions, like
double inversion recovery (DIR), [9-11] contributed to a
surge in studies investigating cortical and subcortical
GM pathology in MS.
Although it has been shown that cortical lesions could
occur secondary to WM damage in relation to Wallerian
degeneration, [12] recent histopathological and MRI stu-
dies have demonstrated that cortical demyelination
mainly occurs spatially distant from WM pathology
[13,14]. It has also been shown that highly inflammatory
subpial cortical demyelination and adjacent meningeal
inflammation can occur very early on in the disease
[15]. Therefore, it is probable that GM could represent
an important initial target of the MS disease process.
The histology-based examination of inflammatory
infiltration in MS brain tissue includes various markers
for T and B cell subsets, dendritic cells, microglia and
macrophages [3]. Application of these immunohisto-
chemistry techniques to GM tissue has revealed a con-
trast with most WM lesions, demonstrating that GM
lesions in progressive MS include considerably less
inflammation than what is observed in the WM. How-
ever, this may simply represent the dynamic evolution
of these lesions over the disease course, which is yet to
be demonstrated unequivocally [4]. It is becoming
apparent from recent biopsy studies that subpial cortical
lesions in early MS are highly inflammatory, with
intense myelin-laden macrophages and lymphocitic infil-
trates similar to active WM lesions, [15,16] whereas in
the chronic stages these lesions are markedly less
inflammatory, well-demarcated and show oligodendro-
cyte, axonal and synaptic loss. [6,8,17]
Although a number of different classifications were
proposed for distinguishing cortical lesions types over
the last decade, [6-8,16] for practical purposes these can
be best grouped in 3 subtypes: leukocortical, intracorti-
cal and subpial [2-4]. GM lesions have also been
described in the cerebellar cortex and hippocampus
[18,19]. It has been postulated that the location of a cor-
tical lesion may influence the immune response [3,4].
The amount of inflammation that is present is variable
depending on the type of cortical lesion. Lesions that
extend through the WM and cortex (leukocortical or
type I) have higher counts of inflammatory cells than
those that are exclusively intracortical (type II) or sub-
pial (Type III), at least in the chronic stage and based
on autopsy material [17,20]. Moreover, there is a close
topographic association between subpial lesions and
meningeal inflammatory infiltrates [15-17,21]. It is cur-
rently believed that meningeal inflammatory aggregates
contribute to both cortical demyelination and MS dis-
ease progression. Ectopic B-cell follicle-like structures
have been reported in the deep sulci of the temporal,
cingulate, insula and frontal cortices of early [15] and
progressive [22] MS patients and are immunoreactive
for Epstein-Barr virus (EBV) [21]. However, the identifi-
cation of EBV infection of meningeal B-cells and its
potential role in MS pathogenesis remains controversial,
as these findings have not yet been confirmed by multi-
ple groups. [22]
There is mounting evidence that about 40% of patients
with clinically isolated syndrome show cortical lesions
on MRI [9]. These data were recently corroborated by
histopathological findings [15]. On the other hand more
than 80% of progressive MS patients present with corti-
cal lesions in advanced stages of the disease [15,17].
Interesting, in progressive forms of MS, cortical demye-
lination in the cerebellum is almost universal, affecting
over 38% of the entire cerebellar cortex on average [19].
The mechanisms responsible for triggering meningeal
inflammation in MS patients are not yet elucidated, and
they should be further investigated in relation to their
role in initiating and perpetuating the disease process.
Determining the role of antigens, environmental and
genetic factors for pathogenesis of cortical pathology in
MS is critical.
Due to inherent structural differences between GM
and WM and as a result of differences in the character-
istics of inflammatory infiltrates, GM lesions maintain a
normal proton concentration and are not detectable as
T2 hyperintense foci like WM lesions [23]. The intro-
duction of DIR in the study of MS played a remarkable
step in better recognition of GM lesions [2]. DIR pro-
vides excellent distinction between GM and WM by
suppressing the signal from normal WM and cerebrosp-
inal fluid [23]. A series of important studies from Geurts
et al. [2] and Calabrese et al. [24] established that on
DIR the cortical lesions are most frequent in patients
with progressive MS, or of male sex or those who have
IgG oligoclonal bands. However, it is now evident that
detection of cortical lesions in vivo on DIR represents
only a limited snapshot of the real cortical and subcorti-
cal GM pathology that is present in MS patients, with
an average sensitivity of only 18% [25]. Subpial cortical
lesions are particularly difficult for DIR to detect. There-
fore, although specificity is high in recently established
pathologically validated DIR scoring guidelines, sensitiv-
ity is very low. [25,26]
MRI and histopathological studies have shown that
GM lesions also exist in other non-cortical GM struc-
tures such as the thalamus, hippocampus, caudate, puta-
men, globus pallidum and others [2]. These structures
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are also affected at the earliest stage, [1] and further
progress with disease evolution [27]. Histopathological
studies did not show an extensive presence of GM
lesions in these structures, when compared to cortical
regions [25]. This may suggest that other mechanisms,
not yet elucidated, may play an important role in med-
iating the damage in subcortical GM. The extensive
connections between the cortical and subcortical struc-
tures, like the thalamus, make these brain structures
particularly vulnerable to pathological changes in other
areas of the brain [12]. The early involvement of subcor-
tical GM damage in MS is certainly very intriguing and
needs to be further studied.
In the last 5 years, numerous cross-sectional and long-
itudinal studies established that GM damage is a better
predictor of physical disability and cognitive impairment
than WM damage [5]. Most studies examining this
argument used novel imaging techniques that can indir-
ectly assess the extent of GM damage, the most impor-
tant being a measurement of GM atrophy [2,5].
Therefore, monitoring the evolution of GM damage by
various imaging techniques is becoming an important
marker in predicting the future disease course and
response to therapy in MS patients. A number of cur-
rent clinical trials examine the effects of immunomodu-
latory treatments on slowing down GM damage over
time.
In conclusion, the review papers by Lucchinetti and
Popescu, [4] Walker and colleagues, [3] Hulst and col-
leagues [2] and Horakova and colleagues [5] represent a
comprehensive update on the role and significance of
GM damage in MS. They also raise a number of impor-
tant new questions and outline comprehensive
approaches to address those questions in years to come.
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